Skip to content
Open access

2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

The 2025/26 influenza vaccine reduced the risk of A(H3N2), A(H1N1)pdm09 and B/Victoria and B/Victoria by over one-third, one-quarter and one-half, respectively.

Abstract

Background: The 2025/26 influenza season included A(H3N2) subclade K predominance with A(H1N1)pdm09 co-circulation and subsequent prolonged influenza B activity. The Canadian Sentinel Practitioner Surveillance Network reports vaccine effectiveness (VE) in the context of genetic and antigenic relatedness to circulating viruses. Methods: We estimated VE by test-negative design among outpatients with medically-attended acute respiratory illness between November and April. We characterized case viruses by whole genome sequencing and hemagglutination inhibition assay. Results: Among 2809/9047 (31%) influenza-positive specimens, 82% (2306/2809) were influenza A with 18% (504/2809) influenza B. Of subtyped influenza A, 85% (1848/2169) were A(H3N2). We sequenced 59% (1099/1848) of A(H3N2) viruses, with 87% (956/1099) subclade K, antigenically-mismatched to subclade J.2 vaccine. VE against A(H3N2) and subclade K was 38% (95% confidence interval: 27%-47%) and 33% (19%-45%). We sequenced 69% (222/323) of A(H1N1)pdm09 viruses, virtually all (n=218) clade 5a.2a.1, including subclades D.3.1 (21%; n=47) and D.3.1.1 (77%; n=171), antigenically-matched to subclade D vaccine. VE against A(H1N1)pdm09, subclades D.3.1 and D.3.1.1 was 28% (4%-47%), -21% (-144%-40%) and 44% (14%-64%). We sequenced 82% (413/504) of influenza B viruses, all B/Victoria, including antigenically-mismatched subclade C.3 (18%; n=74) with D197N gain-of-glycosylation, and antigenically-matched subclade C.5 (82%; n=339) relative to subclade C vaccine. VE against influenza B, subclades C.3 and C.5 was 55% (41%-66%), 10% (-60%-49%) and 68% (51%-79%). Conclusions: The 2025/26 influenza vaccine reduced the risk of A(H3N2), A(H1N1)pdm09 and B/Victoria by over one-third, one-quarter and one-half, respectively. Laboratory-based indicators of vaccine match remain uncertain proxies for actual vaccine protection, reinforcing importance of annual epidemiological monitoring of VE.

Read PDF

Similar papers

#protein folding Open access Sep 2026

Influenza A(H3N2) Subclade K During the 2025–26 Season and Differential Humoral Responses in Vaccinated Individuals Versus Vaccinated Convalescents in Israel

Natural infection provides a more pronounced increase in both binding and neutralizing antibodies compared to vaccination alone, which might contribute to broader cross-protection against antigenically drifted variants.

Ital Nemet, N. Zuckerman, N. Atari et al. · 0 citations
Oct 2026

Influenza B Circulation and Vaccine Effectiveness Against Medically Attended Outpatient Influenza B Illness, United States, 2016-17 Through 2024-25.

BACKGROUND Influenza B vaccine effectiveness (VE) has varied by season, lineage, antigenic drift, and vaccine composition. After B/Yamagata detection ceased globally, trivalent vaccines containing B/Victoria were reintroduced in 2024-25. We evaluated influenza B circulation and VE across eight analyzed seasons spanning...

J. Meeker, Ashley M. Price, Emily T. Martin et al. · 0 citations
Open access Oct 2026

Study of Molecular Genetic Characteristics of Influenza A(H1N1) Viruses Identified During Monitoring in Kazakhstan (2023–2026)

Background/Objectives: Seasonal influenza threatens global public health through rapid mutations. This study evaluated the prevalence and molecular-genetic characteristics of seasonal influenza viruses circulating in Kazakhstan during the 2023–2026 epidemic seasons. Methods: Nasopharyngeal swabs (n = 1756) and serum sa...

N. Klivleyeva, T. Glebova, A. Baimukhametova et al. · 0 citations
Open access Oct 2026

Update to the CDC influenza A(H3) subtyping assay for improved detection of influenza A(H3N2) viruses, including subclade K viruses

ABSTRACT Influenza A(H3N2) viruses circulate globally and cause respiratory illness. The FDA-cleared CDC Human Influenza Virus Real-Time RT-PCR Influenza A (H3/H1pdm09) Subtyping assay is used to subtype seasonal influenza A viruses. However, emerging mutations in the H3 reverse primer region raised concerns about redu...

Bo Shu, Jimma Liddell, Phili Wong et al. · 0 citations
Oct 2026

End-of-season influenza vaccine effectiveness against a(H3N2) and B/Victoria in Beijing, China, 2025/26 season.

INTRODUCTION This study aimed to estimate the end-of-season influenza vaccine effectiveness (VE) against A(H3N2) and B/Victoria in the 2025/26 season in Beijing, China. METHODS We used a test-negative design to assess influenza VE among outpatients with influenza-like illness (ILI) enrolled through the Beijing influe...

Jiao-Jiao Zhang, Ying Shen, Wei-Xian Shi et al. · 0 citations
Open access Oct 2026

Mathematical AI Predicts 40% and 57% Influenza Vaccine Effectiveness Against H1N1 and H3N2, Respectively, for the 2026-–2027 U.S. Season

Background Clinical influenza vaccine effectiveness (VE) has often been low over the past two decades, highlighting the need for preseason VE forecasting. Timely forecasts could help health authorities plan prevention strategies and allocate healthcare resources. However, preseason forecasting of clinical influenza VE...

Xiang-Xiang Wang, Guo-Wei Wei · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.